Abstract 1499
Background
Tumor growth depends on pro-angiogenic vascular endothelial growth factors (VEGF-A/-B) via binding to VEGF receptors (VEGFR1 and VEGFR2) that are biomarkers of tumor angiogenesis. Importantly, interfering with this interaction by small molecules impairs tumor growth and angiogenesis.
Methods
A novel peptide (known as VGB3) was synthesized using a solid-phase peptide synthesis (SPPS) procedure on 2-chlorotrityl chloride (2-CTC) resin. A disulfide bridge was formed in the peptide and it was purified using RP-HPLC. Recombinant His-tagged VEGFR1D2 obtained from inclusion bodies and purified on a Ni2+-NTA agarose resin. The equilibrium constant for the binding of VGB3 to VEGFR1-D2 molecule was determined by microscale thermophoresis (MST). The accumulation of the peptide in 4T1 mammary carcinoma tumors (MCTs) was assessed using 2D optical imaging. Anti-angiogenic activity of VGB3 were investigated using MTT, scratch assay, and two- as well as three-dimensional angiogenesis assays. Downstream signaling pathways were assessed by quantitative estimation of protein expression using western blotting and immunohistochemistry. (IHC).
Results
We have indicated that VGB3 is able to block VEGFR1-D2 in human umbilical vein endothelial cells (HUVECs) and 4T1 mammary carcinoma tumor (MCT) cells. This resulted in inhibition in proliferation of HUVEC, 4T1 MCT, and U87 glioblastoma cells and MST results reveals that VGB3 is a high-affinity (Kd=1.96± 0.69 µM, n = 3, P < 0.0001) binder to VEGFR1-D2. Moreover, fluorescence imaging in Balb/c mice demonstrated that fluorescein isothiocyanate (FITC)-VGB3 accumulated in tumors. VEGFA-stimulated proliferation, migration, and 2 and 3D tube formation in HUVECs were strongly inhibited by VGB3 (n = 3, P < 0.0001). In a murine 4T1 MCT model, VGB3 strongly inhibited AKT and ERK1/2 phosphorylation and tumor cell downstream signaling pathways associated with proliferation, migration, and angiogenesis, and led to the increased apoptosis index and suppression of systematic spreading of the tumor compared to PBS-treated controls.
Conclusions
These results indicate that VGB3 may be applicable for antiangiogenic and antitumor therapy.
Clinical trial identification
Editorial acknowledgement
S. Mohsen Asghari and Prof. Matthew Groves
Legal entity responsible for the study
S. Mohsen Asghari and Matthew Groves.
Funding
University of Guilan.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1735 - mTOR inhibition in the treatment of resistant breast cancer
Presenter: María Rodriguez
Session: Poster Display session 1
Resources:
Abstract
6068 - Study of Photodynamic therapy in vitro
Presenter: Irene Jiménez Munguía
Session: Poster Display session 1
Resources:
Abstract
3011 - The potential of neratinib plus dasatinib in overcoming and preventing neratinib resistance in HER2-positive breast cancer models
Presenter: Neil Conlon
Session: Poster Display session 1
Resources:
Abstract
2644 - Novel HDACi, MHY446, induces apoptosis via regulation of mitochondria-endoplasmic reticulum interaction in HCT116 human colorectal cancer cells
Presenter: Nam Deuk Kim
Session: Poster Display session 1
Resources:
Abstract
3085 - Dual inhibition of TGF-β and AXL as a novel treatment for colorectal cancer
Presenter: Davide Ciardiello
Session: Poster Display session 1
Resources:
Abstract
1314 - PARP inhibition enhances cisplatin sensitivity in cervical cancer by modulating β-catenin signaling
Presenter: Minakshi Mann
Session: Poster Display session 1
Resources:
Abstract
2417 - Synergistic effect of DSF combined treatment with cisplatin in atypical teratoid/rhabdoid tumors (AT/RT)
Presenter: Seung Ah Choi
Session: Poster Display session 1
Resources:
Abstract
1149 - Reactive oxygen species induced by OSU-A9 inhibit the growth of duodenal cancer and gastric cancer cells through dephosphorylating intranuclear pyruvate kinase muscle isozyme M2
Presenter: Li-Yuan Bai
Session: Poster Display session 1
Resources:
Abstract
1862 - New therapy for intrahepatic cholangiocarcinoma targeted to cancer associated fibroblasts
Presenter: Takahiro Yamanaka
Session: Poster Display session 1
Resources:
Abstract
782 - Macrophage-cancer cell fusion is mediated by Phosphatidylserine-CD36 receptor interaction and induced by ionizing radiation
Presenter: Ivan Shabo
Session: Poster Display session 1
Resources:
Abstract